› MBiotech Faculty Lead | Digital Health Technologies
Department of Biology
Jayson Parker is Faculty Lead for Digital Health Technologies for the Master of Biotechnology Program. He is also an Associate Professor (Teaching Stream) in the Department of Biology at the University of Toronto Mississauga and is cross-appointed to the Institute of Biomaterials & Biomedical Engineering (BME) at the University of Toronto. In addition, he has lectured in the Faculty of Law. He was a medical advisor to the hedge fund Burlington Capital.
Previously, he was a medical liaison operating in medical affairs for the pharmaceutical companies Novo Nordisk and Schering AG.
He has worked in the investment banking industry as a buy side biotechnology stock analyst for Investor’s Group and Bolton Trembley. He was the Director of Equity Research (Medical) for AIC Limited (now Portland).
As a research associate, he has worked for the Addiction Research Foundation (now CAMH) on animal models of alcohol abuse. In addition, he joined the medical imaging department at Sunnybrook Hospital and conducted research on Alzheimer patients through 3 dimensional reconstructions of patient brains from MRI scans.
He obtained his Ph.D. in Physiology (neuroscience focus) based on his research on brain trauma at the University of Toronto and his MBA from Wilfried Laurier University. His Master’s degree from the University of Toronto focused on the neurobiology of cocaine addiction.
Lastly, he is an active Dungeons & Dragons player.
1 › Clinical Trial failure rates: Quantification of the risk that trials will fail during clinical testing for specific patient populations. We are now using advanced machine learning tools with a focus on biomarkers.
2 › Digital Health: “Dark data” in health project explores how biometric data used in combination can predict the effect of lifestyle choices on performance within 24 hours with respect to cognition and physical performance. This study is still in the data collection phase.
3 › Medical Device Regulation: How products are regulated spanning medical devices, digital health products and health products. Medical device ancestry of heart lung machines and digital health regulation are 2 projects nearing closure.
- Mohamed, L., M., S. Manjrekar, D. Ng, A. Walsh, G. Lopes and J. L. Parker. The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs. Submitted The Oncologist (revisions).
- Dhillon, S., G. Lopes and J. L. Parker. The Effect of Biomarkers on Clinical Trial Risk in Gastric Cancer. Journal of Clinical Oncology (in review).
- Li, A., J. Dhanraj, G. Lopes and J. L. Parker (2021). Biomarker use in lymphoma subtypes. Hematological Oncology. 39: 105-113. Impact Factor 2.8
- Parker, J.L., S. Kuzulugil, K. Pereverzev, S. Mach, G. Lopes, Z. Shah, A. Weerasinghe, D. Rubinger, A. Falconi, A. Bener, B. Caglayan, R. Tangri and N. Mitsakakis (2021). Does biomarker use in oncology improve clinical trial risk? Cancer Medicine. 10(6): 1955-1963. Impact Factor 3.4
› Direct Link All Publications: https://www.researchgate.net/profile/Jayson_Parker/